Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Meyer

Showing results (451-460 of 476) with videos related to

Pageof 48
Sort By:
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 11, 2025
Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter studySusanne Spittel, Torsten Grehl, Patrick Weydt, et al.
Journal of Neurology|August 14, 2024
Clinical characterization of common pathogenic variants of SOD1-ALS in GermanyMaximilian Wiesenfarth, Yalda Forouhideh-Wiesenfarth, Zeynep Elmas, et al.
Annals of Surgery|August 2, 2021
Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled TrialsDominique L Birrer, Henriette Golcher, Riccardo Casadei, et al.
Psychosomatic Medicine|January 14, 2023
Type D Personality as a Risk Factor for Adverse Outcome in Patients With Cardiovascular Disease: An Individual Patient-Data Meta-analysisPaul Lodder, Jelte M Wicherts, Marijn Antens, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 13, 2016
Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening studyAngelica Nordin, Chizuru Akimoto, Anna Wuolikainen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 14, 2018
Comprehensive analysis of the mutation spectrum in 301 German ALS familiesKathrin Müller, David Brenner, Patrick Weydt, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
European Journal of Neurology|June 11, 2024
Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter studyThomas Meyer, Marie Dreger, Torsten Grehl, et al.
The Lancet. Neurology|October 18, 2024
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trialJan C Koch, Andreas Leha, Helen Bidner, et al.
Journal of Neurology|March 30, 2019
Prognostic factors in ALS: a comparison between Germany and ChinaJohannes Dorst, Lu Chen, Angela Rosenbohm, et al.
Pageof 48

Showing results (451-460 of 476) with videos related to

Sort By:
Pageof 48
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|September 11, 2025
Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter studySusanne Spittel, Torsten Grehl, Patrick Weydt, et al.
Journal of Neurology|August 14, 2024
Clinical characterization of common pathogenic variants of SOD1-ALS in GermanyMaximilian Wiesenfarth, Yalda Forouhideh-Wiesenfarth, Zeynep Elmas, et al.
Annals of Surgery|August 2, 2021
Neoadjuvant Therapy for Resectable Pancreatic Cancer: A New Standard of Care. Pooled Data From 3 Randomized Controlled TrialsDominique L Birrer, Henriette Golcher, Riccardo Casadei, et al.
Psychosomatic Medicine|January 14, 2023
Type D Personality as a Risk Factor for Adverse Outcome in Patients With Cardiovascular Disease: An Individual Patient-Data Meta-analysisPaul Lodder, Jelte M Wicherts, Marijn Antens, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|December 13, 2016
Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening studyAngelica Nordin, Chizuru Akimoto, Anna Wuolikainen, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|April 14, 2018
Comprehensive analysis of the mutation spectrum in 301 German ALS familiesKathrin Müller, David Brenner, Patrick Weydt, et al.
Plos One|May 21, 2014
Safety, pharmacokinetic, and functional effects of the nogo-a monoclonal antibody in amyotrophic lateral sclerosis: a randomized, first-in-human clinical trialVincent Meininger, Pierre-François Pradat, Andrea Corse, et al.
European Journal of Neurology|June 11, 2024
Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter studyThomas Meyer, Marie Dreger, Torsten Grehl, et al.
The Lancet. Neurology|October 18, 2024
Safety, tolerability, and efficacy of fasudil in amyotrophic lateral sclerosis (ROCK-ALS): a phase 2, randomised, double-blind, placebo-controlled trialJan C Koch, Andreas Leha, Helen Bidner, et al.
Journal of Neurology|March 30, 2019
Prognostic factors in ALS: a comparison between Germany and ChinaJohannes Dorst, Lu Chen, Angela Rosenbohm, et al.
Pageof 48